Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest BD Diagnostics Stories

2013-07-30 12:29:34

New collaboration will expand access to wide range of CAP resources through BD's established presence in emerging markets NORTHFIELD, Ill. and FRANKLIN LAKES, N.J., July 30, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and the College of American Pathologists (CAP), the world leader in laboratory quality assurance and improvement, today announced the launch of a new strategic alliance...

2013-07-12 23:34:49

Computer-assisted screening provides the latest advancement for cervical cancer detection. Berkeley Heights, NJ (PRWEB) July 11, 2013 Summit Medical Group today announced it has begun using state-of-the-art technology designed to improve diagnosis of cervical cancer and its precursors. Summit Medical Group now employs the BD FocalPoint™ GS Imaging System developed by BD Diagnostics – Women’s Health and Cancer (Franklin Lakes, NJ). Approved by the FDA for screening BD SurePath™ Pap...

2013-05-02 08:35:17

FRANKLIN LAKES, N.J., May 2, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the second fiscal quarter ended March 31, 2013, representing an increase of 3.7 percent from the prior-year period, or 4.1 percent on a foreign currency-neutral basis. "We continued to deliver solid performance in the second quarter. Our results for the first half of the year give us the...

2013-04-27 04:20:29

SPARKS, Md., April 27, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to sell and provide front-line technical support for the co-labeled BD(TM) Bruker MALDI Biotyper(TM) System. Microbial identification and antimicrobial susceptibility testing is the end-point of the majority of work a microbiology lab performs on a daily basis and is very time consuming. The BD(TM)...

2013-04-09 08:29:54

BD MAX(TM) Cdiff Assay Receives FDA Clearance BALTIMORE, April 9, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it received FDA clearance to market the BD MAX(TM) Cdiff Assay in the United States. The assay is performed on the fully-automated BD MAX(TM) System and is designed to rapidly and accurately detect the toxin B gene (tcdB), which has been shown to be essential to...

2013-04-08 08:30:21

Leading Canadian Laboratory Services Provider to Implement BD Kiestra(TM) Total Laboratory Automation Platform by Third Quarter 2013 MISSISSAUGA, Ontario, April 8, 2013 /PRNewswire/ -- CML HealthCare Inc. (TSX: CLC) (the "Company" or "CML"), a leading community-based provider of laboratory and medical imaging services in Ontario and British Columbia, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement for CML...

2013-02-28 08:29:52

Blood Culture Systems Comparison Study Shows BD BACTEC(TM) Plus Aerobic Medium Provides Statistically Significant Differences in Bacterial Recovery for Patients on Antimicrobial Therapy BALTIMORE, Feb. 28, 2013 /PRNewswire/ -- A new study, published in the journal Clinical Infectious Diseases, demonstrates how treatment with broad-spectrum antibiotics can impact the ability to detect bacteria in blood samples from potentially septic patients. It also highlights the importance of...

2013-02-05 08:33:20

FRANKLIN LAKES, N.J., Feb. 5, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012, representing an increase of 3.7 percent from the prior-year period, or 5.2 percent on a foreign currency-neutral basis. "We are very pleased with our start to fiscal year 2013," said Vincent A. Forlenza, Chairman, Chief Executive Officer and...

2012-11-07 08:26:23

FRANKLIN LAKES, N.J., Nov. 7, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.967 billion for the fourth fiscal quarter ended September 30, 2012, representing a decrease of 1.1 percent from the prior-year period, or an increase of 4.7 percent on a foreign currency-neutral basis. For the full fiscal year ended September 30, 2012, BD reported revenues of $7.708 billion, representing an...

2012-10-15 07:29:01

BALTIMORE and CAMBRIDGE, England, Oct. 15, 2012 /PRNewswire/ -- BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21, a global leader in personalized healthcare diagnostics, announced today that they will collaborate to develop oncology assays for the BD MAX(TM) fully automated, bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD...